NLRP3 and colitis: The above results are in line with a recent study showing that treatment of animals with spontaneous chronic colitis (Winnie mice) with a specific NLRP3 inhibitor (MCC950) counteracted bowel inflammation, improving both the macroscopic and histological features of colitis and reducing significantly the release of pro-inflammatory cytokines, including TNF levels (Perera et al., 2018).